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The European Headache and Migraine Trust 
International Congress (EHMTIC) was held 
from 20 to 23 September in London, UK. The 
scientific program of this biennial congress 
included several informative teaching courses on 
experimental techniques for migraine research 
as well as clinical management of migraine and 
other primary headaches. Tobias Kurth from 
Bordeaux University (Bordeaux, France) opened 
the congress with the MacDonald Critchley lec-
ture on migraine genetics epidemiology. The sci-
entific core of the congress were multiple poster 
sessions covering basic laboratory and experi-
mental clinical science on novel aspects of the 
pathophysiology of headache disorders, clinical 
aspects of headache care and recent advances in 
the acute and preventative treatment of migraine. 
Beside the poster sessions, lectures were given 
for the awarding of the Enrico Greppi Award 
and the Giuseppe Nappi Cluster Headache 
Award conferred to Sait Ashina (Beth Israel 
Medical Center, NY, USA) and Delphine Magis 
(University of Liège, Liège, Belgium) for their 
respective research contributions on depression 
and risk of transformation of episodic to chronic 
migraine, and central mechanisms of occipital 
nerve stimulation (ONS) in cluster headache. 
The Migraine Trust lecture was given by Karl 
Messlinger (University of Erlangen–Nürnberg, 
Germany), who provided an extensive overview 
of the neurobiology of migraine. Finally, in the 
Jes Olesen EHF lecture Rigmor Jensen (Danish 
Headache Center, Copenhagen, Denmark) 
presented the recent advances and challenges in 
headache research.
Neurostimulation is of increasing interest 
for the treatment of primary headaches. Initial 
experiences with invasive methods, such as deep 
brain stimulation for drug-refractory cluster 
headache, have been effective but were ham-
pered by severe side effects. Research efforts are 
now being focused on noninvasive or minimally 
invasive neurostimulation therapies that could 
be used in less disabled patients. A variety of 
neurostimulation devices and first data about 
their potential efficacy were presented at the 
conference and are reviewed here.
Noninvasive neurostimulation devices
Transcranial magnetic stimulation
Transcranial magnetic stimulation (TMS) is an 
established method to modulate cortical excit-
ability and has been used for several  neurological 
purposes for many years. Holland et al. 
 demonstrated in an in vivo model of migraine, 
that single-pulse TMS (sTMS) was able to inhibit 
Jan Hoffmann*1 and 
Delphine Magis2
1Department of Neurology, 
Charité – Universitätsmedizin Berlin, 
Charitéplatz 1, 10117 Berlin, Germany
2Headache Research Unit, Department 
of Neurology, University of Liège, 
Boulevard du 12ème de Ligne 1, 
4000 Liège, Belgium
*Author for correspondence:  
Tel.: +49 30 450 560 276  
Fax: +49 30 450 560 912  
jan.hoffmann@charite.de
3rd European Headache and Migraine Trust International Congress
London, UK, 20–23 September 2012
The pathophysiological understanding of migraine and other primary headaches has been 
substantially improved over the last 20 years. A milestone that paved the way for successful 
research was the development of the International Classification of Headache Disorders 
published by the International Headache Society in 1988. The classification facilitated a clear 
clinical diagnosis of headache disorders and allowed research efforts to be focused on clearly 
defined syndromes. Recent advances in the understanding of headache disorders have been 
driven by the availability of new research tools, such as advanced imaging techniques, genetic 
tools, pharmaceutical compounds and devices for electrical or magnetic stimulation. The latest 
scientific and clinical advances were presented at the recent European Headache and Migraine 
Trust International Congress (EHMTIC) in London (UK).
Scientific advances in headache 
research: an update on 
neurostimulation
Expert Rev. Neurother. 13(1), 15–17 (2013)
Expert Review of Neurotherapeutics





For reprint orders, please contact reprints@expert-reviews.com
 Expert Rev. Neurother. 13(1), (2013)16
Meeting Report
cortical spreading depression [1]. A recent randomized controlled 
trial (RCT) suggested a positive, although modest effect of sTMS 
for the acute treatment of migraine with aura [2]. At this year’s 
EHMTIC, sTMS was presented in the context of a postmarket 
pilot program of the SpringTMS™ device for the acute treatment 
of migraine [3]. In this study, 37 patients (24 migraine with aura, 
and 13 migraine without aura) used the device in an outpatient 
setting over three consecutive months. A total of 504 attacks of 
migraine with aura and 273 attacks of migraine without aura were 
treated. A significant reduction or alleviation of migraine pain 
was reported by 73% of the patients, while an improvement of 
migraine-associated symptoms was reported by 63%. No adverse 
events were reported. Taken together with the previous sTMS 
RCT, these results indicate that sTMS could be a promising acute 
migraine treatment. However the sample size was small and objec-
tive data from headache diaries are lacking. Further well-conducted 
RCTs and pharmacoeconomic data are warranted. In his invited 
new scientist lecture, A Vigano (Sapienza University of Rome, 
Rome, Italy) explained that excitatory intermittent theta burst 
repetitive pulse TMS (rTMS) of the visual cortex (i-TBS) applied 
to healthy volunteers could induce changes in cortical respon-
siveness, which should be able to normalize the cortical interic-
tal neuro physiological abnormalities found in migraineurs, and 
so become a valuable migraine preventive treatment [4]. Clinical 
results of i-TBS in episodic migraineurs are eagerly awaited.
Transcranial direct current stimulation
Besides TMS, transcranial direct current stimulation (tDCS) is 
another central neuromodulatory technique that is able to modify 
neuronal firing, but previous trials performed in migraine dis-
closed inconsistent results [5]. Vigano presented the preliminary 
results of a proof-of-concept trial of excitatory anodal tDCS of the 
visual cortex performed in seven episodic migraineurs as preven-
tive treatment [6]. After 2 months of treatment with anodal tDCS, 
there was on average a significant reduction in migraine frequency 
(-36.65%) and attack duration (-43.25%), and the interictal 
habituation of visual evoked potentials tended to increase. Larger 
RCTs with anodal tDCS may thus be worthwhile in migraine.
Transcutaneous vagus nerve stimulation
Magis and Jean Schoenen (University of Liège) presented data about 
their initial experience with a transcutaneous vagus nerve stimula-
tion (tVNS) device (Gammacore®). Twelve migraine without aura 
(five patients with medication-overuse headache), four trigemi-
nal autonomic cephalalgia (TAC) and two hemicrania continua 
(HC) patients were included. Neurostimulation was performed 
three times daily over 90 s as preventive therapy. At the time of 
present ation, results were available for 13 patients. Out of these, ten 
patients had stopped the treatment before completion of the study 
due to lack of efficacy and/or significant side effects. A total of three 
patients (one medication overuse headache, one TAC and one HC) 
experienced a significant reduction in attack frequency, in two of 
them the benefit remained after 7-month follow-up [7]. In another 
trial, Nesbitt et al. used tVNS to treat 14 patients suffering from 
cluster headache (CH; seven chronic CHs and seven episodic CHs) 
during a median period of 13 weeks. Mean subjective improvement 
was 60% in 13 patients. Twelve patients were able to reduce or even 
stop their previous preventive treatment. The same authors also 
used tVNS to relieve pain in two HC patients previously treated 
with ONS [8]. Taken together, these results indicate that more trials 
are needed to clarify a potential e fficacy of tVNS and that treatment 
of TACs could be a valuable indication.
Transcutaneous supraorbital stimulation
Case reports using invasive supraorbital stimulation have shown 
promising results [5]. Along the same line, the efficacy and safety 
of a transcutaneous supraorbital nerve stimulator (tSNS), the 
Cefaly® device, has been tested in a multicenter, double-blind, 
randomized, sham-controlled trial in 67 episodic migraineurs 
[9]. Patients were randomly assigned to verum or sham stimula-
tion after a 1-month run-in period. tSNS was performed daily 
for 20 min during 3 months. The authors observed a significant 
reduction of monthly migraine days and attacks (both p = 0.04) 
and acute antimigraine drug intake (p = 0.007). The 50% 
responder rate was significantly higher in the verum (38.1%) 
than in the sham group (12.1%). There were no adverse events. 
These results suggest that tSNS with the Cefaly device might offer 
a promising alternative to drugs for the preventive treatment of 
migraine. Hence, if its effectiveness is slightly lower than the best 
pharmacologic prophylactic treatment, such as topiramate, the 
absence of adverse events constitutes a real advantage.
Invasive neurostimulation devices
Sphenopalatine ganglion neurostimulation
Schoenen presented the final results of the multicenter European 
Pathway CH-1 RCT on the efficacy of sphenopalatine ganglion 
stimulation (SPGS) for the treatment of chronic CH, using the 
ATI® implantable microstimulator [10]. The preliminary results 
reported at the annual meeting of the American Academy of 
Neurology indicated that SPGS induced a significant reduction 
of frequency and intensity of CH [11]. The SPGS ATI device is 
surgically implanted into the pterygopalatine fossa and it elec-
trically stimulates the sphenopalatine ganglion to disrupt the 
trigeminal parasympathetic reflex that involves the sphenopala-
tine ganglion. Stimulation is triggered by the patient using a 
handheld remote control. Available data suggest that this micro-
stimulator is MR-safe. The blinded experimental period of the 
CH-1 trial was completed by 27 patients. Pain relief was achieved 
in 67% of headache attacks with full stimulation versus 8% for 
placebo. Twenty six percent of patients experienced a significant 
pain relief in ≥50% of the attacks, 37% reported a frequency 
improvement of at least 50% and 7% had both effects. As a 
result of the surgical procedure 47% of the patients experienced 
transient and mild-to-moderate numbness in the second branch 
of the trigeminal nerve.
Occipital nerve stimulation
Several open trials have recently suggested that ONS could be 
effective in the prevention of drug-resistant chronic CH [12–16] 




During the conference J Vesper et al. (Heinrich–Heine 
University Hospital, Düsseldorf, Germany) presented a study in 
which they investigated the outcome of 20 patients with various 
therapy-refractory chronic headaches under ONS. Nine patients 
suffered from chronic migraine, one patient had a thalamic infarc-
tion, one CH, four tension type headache and five recurrent 
cervico genic headache. Patients were followed up over 3 months. 
A total of 16 out of the 20 patients experienced a significant reduc-
tion in pain intensity. No adverse events were reported. This study 
on a variety of refractory headache types well illustrates that the 
mechanism of action of ONS in headache is absolutely nonspecific 
and does not act on the disease generator, as suggested before [15,20].
Conclusion
The high amount of neurostimulation trials and case reports 
presented at the 3rd EHMTIC contrasts with the obvious lack 
of new specific drugs in the headache field. Hence, no acute 
migraine-specific drugs have been released since the advent of 
triptans 20 years ago, and the hopes raised by gepants (CGRP 
antagonists), ditans (5HT
1F
 agonists) and the CSD-blocker 
tonabersat are somewhat disappointing. Central neuromodula-
tion techniques such as TMS or tDCS could become the first 
migraine-specific preventive therapies, as all preventive drugs used 
up to now are not specific to the disease. Even if the preliminary 
results obtained with minimally and noninvasive neurostimula-
tion therapies in headache are promising, large well-conducted 
RCTs are missing for most devices and optimal device settings 
and mode of action are unknown.
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